MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$4,941K
Free Cash flow
-$5,387K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Accounts receivable, net
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Accrued liabilities and other
Foreign currency transactions
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-06-30
Inventories, long-term
1,451
Inventories
2,394
Accrued liabilities and other
-4,376
Stock-based compensation
6,243
Net loss
-8,436
Other assets
158
Other current assets
-338
Accounts receivable, net
-3,948
Accounts payable
3,654
Foreign currency transactions
2,752
Depreciation and amortization
124
Net cash used in operating activities
-5,260
Purchase of property and equipment
127
Net cash used in investing activities
-127
Proceeds from exercised stock options
446
Net cash provided by financing activities
446
Net decrease in cash and cash equivalents
-4,941
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercised
stock options
$446K
Net cash provided by
financing activities
$446K
Net decrease in cash
and cash...
-$4,941K
Canceled cashflow
$446K
Stock-based compensation
$6,243K
Accounts receivable, net
-$3,948K
Accounts payable
$3,654K
Other current assets
-$338K
Depreciation and
amortization
$124K
Net cash used in
operating activities
-$5,260K
Canceled cashflow
$14,307K
Net cash used in
investing activities
-$127K
Net loss
-$8,436K
Accrued liabilities and
other
-$4,376K
Foreign currency
transactions
$2,752K
Inventories
$2,394K
Inventories, long-term
$1,451K
Other assets
$158K
Purchase of property and
equipment
$127K
Buy us a coffee
Y-mAbs Therapeutics, Inc. (YMAB)
Y-mAbs Therapeutics, Inc. (YMAB)